1. The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study--results from 29 358 German patients.
- Author
-
van Ahlen H, Zumbé J, Stauch K, and Landen H
- Subjects
- Aged, Germany, Humans, Imidazoles adverse effects, International Cooperation, Male, Middle Aged, Penile Erection, Phosphodiesterase Inhibitors adverse effects, Phosphodiesterase Inhibitors pharmacology, Piperazines adverse effects, Prospective Studies, Safety, Sulfones adverse effects, Sulfones pharmacology, Surveys and Questionnaires, Time Factors, Treatment Outcome, Triazines adverse effects, Triazines pharmacology, Vardenafil Dihydrochloride, Erectile Dysfunction drug therapy, Imidazoles pharmacology, Piperazines pharmacology
- Abstract
We assessed the safety, efficacy and patient acceptability of vardenafil (Levitra, Bayer HealthCare, Leverkusen, Germany) under real-life conditions in patients with erectile dysfunction (ED) in a multinational post-marketing surveillance study. An initial and up to two follow-up visits were documented for 29 358 German ED patients receiving vardenafil. Patients were interviewed about overall treatment success, and individual sexual attempts were evaluated in a patient questionnaire. Overall erectile improvement was reported by 93.9% of physicians, and similar improvement rates were reported for both 10 mg and 20 mg vardenafil dosages. Most patients experienced improved erections after the first (73.6%) or second (88.5%) tablet. Sexual attempts were successful with respect to partner penetration in 94.9% of patients and with respect to maintenance of erection during intercourse in 87.7% of patients. Adverse drug reactions were very rare (1.3% of patients). Vardenafil was highly effective, reliable and well tolerated in ED patients treated under real-life conditions.
- Published
- 2005
- Full Text
- View/download PDF